Research Topics
Species | Vali A PapadimitrakopoulouSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Pilot randomized phase II study of celecoxib in oral premalignant lesionsVassiliki A Papadimitrakopoulou
Department of Thoracic Head, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 14:2095-101. 2008..In this pilot randomized phase II study, we evaluated the efficacy and safety of the COX-2 inhibitor celecoxib in patients with oral premalignant lesions (OPL)...- Optimizing biomarkers and endpoints in oral cancer chemoprevention trialsWilliam N William
Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030
Cancer Prev Res (Phila) 6:375-8. 2013..In this commentary, the complexities involved in defining optimal biomarkers and endpoints for oral cancer prevention trials and the development of dietary chemoprevention agents are discussed. Cancer Prev Res; 6(5); 375-8. ©2013 AACR... - Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancerVassiliki Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, Texas 77030, USA
J Thorac Oncol 7:1315-26. 2012.... - Cyclin D1 and cancer development in laryngeal premalignancy patientsVassiliki Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 432, Houston, TX 77030, USA
Cancer Prev Res (Phila) 2:14-21. 2009..04) and within each CD1 genotype group. These findings support CD1 genotype and protein expression as important risk markers for laryngeal cancer and suggest future trials targeting upstream regulators of CD1 transcription... 
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancyVassiliki A Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 27:599-604. 2009....
The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapyVassiliki Papadimitrakopoulou
MD Anderson Cancer Center, Houston, Texas 77030, USA
J Thorac Oncol 1:749-51. 2006..We review current information on the therapeutic manipulation of these targets and describe early clinical data in lung cancer...- The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesisVassiliki A Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Cancer Lett 239:136-43. 2006.... - Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumorsVali Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 11:4151-9. 2005.... - Biochemoprevention for dysplastic lesions of the upper aerodigestive tractV A Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
Arch Otolaryngol Head Neck Surg 125:1083-9. 1999.... - Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesionsVassiliki A Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Epidemiol Biomarkers Prev 11:1605-10. 2002..o. cavity, a series of biomarkers extensively used in previous chemoprevention trials, including chromosome polysomy (CP), proliferative status, p53 expression and gene mutations, and loss of heterozygosity at 9p, 3p, and 17p... - Chemoprevention of head and neck cancer: an updateVali A Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Curr Opin Oncol 14:318-22. 2002..Chemoprevention research is based on the increasing body of knowledge of the biology underlying head and neck tumorigenesis and is expected to ultimately result in a decrease in the incidence of head and neck cancer... - Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer developmentV A Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1500 Holcombe Boulevard, Houston, TX 77030, USA
Clin Cancer Res 7:3127-34. 2001.... - Carcinogenesis of head and neck cancer and the role of chemoprevention in its reversalV A Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Curr Opin Oncol 12:240-5. 2000..Newly acquired knowledge in the field of tumor biology and of the genetic changes underlying carcinogenesis through the use of new molecular technology represents the basis on which chemoprevention efforts should be based... - Outcomes of patients with tonsillar carcinoma treated with post-tonsillectomy radiation therapyGokcen Yildirim
The University of Texas M D Anderson Cancer Center, Department of Radiation Oncology, Unit 97, 1515 Holcombe Blvd, Houston, TX 77030, USA
Head Neck 32:473-80. 2010..Our aim was to evaluate the therapeutic outcomes of patients with squamous cell carcinoma of the tonsil that underwent tonsillectomies followed by radiotherapy... - Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)Hai T Tran
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030, USA
Invest New Drugs 29:499-505. 2011..To assess the pharmacokinetics and evaluate potential drug-drug interactions between erlotinib, paclitaxel and carboplatin... - The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapyRoy S Herbst
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 95:340-53. 2002..The authors conducted a formal Phase II trial to evaluate the efficacy of this combination in both untreated and previously treated patients with Stage IIIB (with pleural effusion) or Stage IV NSCLC... - Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancerGeorge R Blumenschein
Department of Thoracic and Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Invest New Drugs 26:81-7. 2008..Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients... - Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatmentIan J Bristol
Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 68:719-30. 2007..To determine the effects of three changes in radiotherapy technique on the outcomes for patients irradiated postoperatively for maxillary sinus cancer... - Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancerFaye M Johnson
Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, USA
Clin Lung Cancer 5:40-5. 2003..With the exception of the 2 deaths, the therapy was well tolerated and active. Phase II evaluation of the regimen in patients with extensive-stage SCLC is ongoing... - Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancerRalph G Zinner
The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 104:2449-56. 2005..The primary objectives of this study were to determine the efficacy and tolerability of a pemetrexed-carboplatin combination as first-line therapy in patients with advanced nonsmall cell lung cancer... - Akt activation correlates with adverse outcome in tongue cancerErminia Massarelli
Department of Head and Neck/Thoracic Medical Oncology, M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 104:2430-6. 2005..CONCLUSIONS: Expression of p-Akt correlated with worse outcome in patients with tongue cancer. This finding highlights the potential role of Akt as a prognostic marker and as a potential target for molecular therapeutics... - Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trialRitsuko Komaki
Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 58:1369-77. 2004..To determine the ability of amifostine to reduce the severity and/or incidence of the acute toxicities of concurrent chemotherapy and radiotherapy (RT) for non-small-cell lung cancer... - Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancerJulie G Izzo
Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
J Natl Cancer Inst 95:198-205. 2003.... - Chemoprevention of head and neck cancerKatrina Y Glover
Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 432, Houston, TX 77030, USA
Curr Oncol Rep 5:152-7. 2003..This article reviews the field of chemoprevention and recent advances in molecular epidemiology and genetics. Current clinical trials are described... - Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancerFaye M Johnson
Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Oncology (Williston Park) 17:17-21. 2003..Patients generally tolerated the weekly alternating chemotherapy with irinotecan/cisplatin and etoposide/cisplatin well, and this combination possessed significant antitumor activity in small-cell lung cancer... - Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinomaVassiliki A Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 98:2214-23. 2003.... - Focus on head and neck cancerLi Mao
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA
Cancer Cell 5:311-6. 2004 - Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesisErminia Massarelli
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 103:952-9. 2005..Longer follow-up of the high percentage of low-risk preneoplastic lesions in the current study and validation in a larger sample size may be required to establish the predictive role of these abnormalities... - High-dose fenretinide in oral leukoplakiaWilliam N William
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Cancer Prev Res (Phila) 2:22-6. 2009..This result is consistent with our clinical finding that high-dose fenretinide did not improve on the historical response rate of lower-dose fenretinide in our previous oral leukoplakia trial... - Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakiaJames L Mulshine
Intervention Section, Cell and Cancer Biology Branch, Department of Pathology and Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1906, USA
Clin Cancer Res 10:1565-73. 2004..This trial evaluated if a topically delivered oral rinse containing ketorolac was as safe as and more effective than oral rinse alone in reducing the area of oral leukoplakia... - An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasiaCharles M Rudin
Medical Center, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
J Clin Oncol 21:4546-52. 2003..The current study sought to establish the feasibility and activity of ONYX-015 administered topically as a mouthwash to patients with clinically apparent and histologically dysplastic lesions of the oral mucosa...